{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-001161","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.462811+00:00","generated_at":"2026-06-20T20:30:50.300091+00:00","sec_items":["1.01","2.03","5.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GE HealthCare completes spin-off from GE; becomes independent public company","bullets":["GE distributed 80.1% of GEHC common stock to GE holders on Jan 3, 2023, at ratio of 1 share per 3 GE shares held.","Drew full $2.0B under 3-year senior unsecured term loan facility entered Nov 2022.","Board of 9 directors appointed; Catherine Lesjak chairs Audit, William Stromberg chairs Talent/Comp.","Non-employee directors receive $125k annual cash retainer and $200k RSU grant per year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-001161","json":"https://secwatch.observer/filing/0001193125-23-001161.json","markdown":"https://secwatch.observer/filing/0001193125-23-001161.md","text":"https://secwatch.observer/filing/0001193125-23-001161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/d386556d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:30:50.300091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9e8bc37d5d33ef2f11795b11ce463a893bea0a4","claim":"GE HealthCare Technologies Inc. incurred term loan of $2.0 billion.","evidence_excerpt":"On the Distribution Date, we drew down the full $2.0 billion available under the Term Loan Agreement.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$2.0 billion"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"150b80a4b3","claim":"Tomislav Mihaljevic was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Tomislav Mihaljevic 58 Talent, Culture, and Compensation Committee and Nominating and Governance Committee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1a2b84f890","claim":"Phoebe L. Yang was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Phoebe L. Yang 53 Talent, Culture, and Compensation Committee and Nominating and Governance Committee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"37efdfa2eb","claim":"Peter J. Arduini was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Peter J. Arduini 58 None","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"423538b1ea","claim":"Lloyd W. Howell, Jr. was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Lloyd W. Howell, Jr. 56 Audit Committee and Talent, Culture, and Compensation Committee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"45983e64f7","claim":"H. Lawrence Culp, Jr. was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"H. Lawrence Culp, Jr. 59 None","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"476374f4b7","claim":"Jan Makela was appointed as CEO, Imaging at GE HealthCare Technologies Inc..","evidence_excerpt":"Jan Makela 54 CEO, Imaging","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"CEO, Imaging"}],"fact_type":"executive_change"},{"claim_id":"489b0b07ee","claim":"Risa Lavizzo-Mourey was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Risa Lavizzo-Mourey 68 Nominating and Governance Committee (Chair)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"52c7b4eea5","claim":"Frank R. Jimenez was appointed as General Counsel and Corporate Secretary at GE HealthCare Technologies Inc..","evidence_excerpt":"Frank R. Jimenez 57 General Counsel and Corporate Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"General Counsel and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"5f95b9770a","claim":"William J. Stromberg was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"William J. Stromberg 62 Audit Committee and Talent, Culture, and Compensation Committee (Chair)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"70f234f6a6","claim":"George A. Newcomb was appointed as Chief Accounting Officer at GE HealthCare Technologies Inc..","evidence_excerpt":"George A. Newcomb 55 Chief Accounting Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"79e3e74ea2","claim":"Anne T. Madden was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Anne T. Madden 58 Audit Committee and Nominating and Governance Committee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"858ef33707","claim":"Helmut Zodl was appointed as Chief Financial Officer at GE HealthCare Technologies Inc..","evidence_excerpt":"Helmut Zodl 50 Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"89aea3f6e9","claim":"Betty D. Larson was appointed as Chief People Officer at GE HealthCare Technologies Inc..","evidence_excerpt":"Betty D. Larson 46 Chief People Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief People Officer"}],"fact_type":"executive_change"},{"claim_id":"9ac606afcb","claim":"Catherine Lesjak was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Catherine Lesjak 63 Audit Committee (Chair)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a3a961a68f","claim":"Rodney F. Hochman was appointed as Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Rodney F. Hochman 67 Audit Committee and Nominating and Governance Committee","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ce5f2fbcb2","claim":"Roland Rott was appointed as CEO, U at GE HealthCare Technologies Inc..","evidence_excerpt":"Roland Rott 51 CEO, U","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"CEO, U"}],"fact_type":"executive_change"},{"claim_id":"e2d0088d52","claim":"Peter J. Arduini was appointed as President, Chief Executive Officer, and Director at GE HealthCare Technologies Inc..","evidence_excerpt":"Peter J. Arduini 58 President, Chief Executive Officer, and Director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Chief Executive Officer, and Director"}],"fact_type":"executive_change"},{"claim_id":"f72b5a0954","claim":"Kevin M. O’Neill was appointed as CEO, Pharmaceutical Diagnostics at GE HealthCare Technologies Inc..","evidence_excerpt":"Kevin M. O’Neill 54 CEO, Pharmaceutical Diagnostics","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"CEO, Pharmaceutical Diagnostics"}],"fact_type":"executive_change"},{"claim_id":"8df73036615749d8ab51bff7988cec8dcd43f728","claim":"GE HealthCare Technologies Inc. completed a disposition involving General Electric Company (closed 2023-01-03).","evidence_excerpt":"On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “we,” “us,” or “our”) by GE to holders of GE common stock on a pro rata basis (the “Spin-Off”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"General Electric Company"},{"label":"Closing","value":"2023-01-03"}],"fact_type":"ma_transaction"},{"claim_id":"2faf27bfdb6e49fe4009421e190590ac748164a6","claim":"GE HealthCare Technologies Inc. entered into Transition Services Agreement with GE (effective 2023-01-03).","evidence_excerpt":"if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"GE"},{"label":"Effective","value":"2023-01-03"}],"fact_type":"material_agreement"},{"claim_id":"4d6231dca5be28a1802cfeec665f0838ae2ea4c5","claim":"GE HealthCare Technologies Inc. entered into Separation and Distribution Agreement with GE (effective 2023-01-03).","evidence_excerpt":"if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"GE"},{"label":"Effective","value":"2023-01-03"}],"fact_type":"material_agreement"},{"claim_id":"6f1516f6a3afa1fb951a71cc60b15c7158246e1d","claim":"GE HealthCare Technologies Inc. entered into Trademark License Agreement with GE (effective 2023-01-03).","evidence_excerpt":"if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"GE"},{"label":"Effective","value":"2023-01-03"}],"fact_type":"material_agreement"},{"claim_id":"ad2067fa18c477ec32dbe6d98b87c065612fa771","claim":"GE HealthCare Technologies Inc. entered into Employee Matters Agreement with GE (effective 2023-01-03).","evidence_excerpt":"if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"GE"},{"label":"Effective","value":"2023-01-03"}],"fact_type":"material_agreement"},{"claim_id":"ff4a758746046850f6bce2b5d84f53f0a588f1f1","claim":"GE HealthCare Technologies Inc. entered into Tax Matters Agreement with GE (effective 2023-01-03).","evidence_excerpt":"if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000119312523001161/0001193125-23-001161-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"GE"},{"label":"Effective","value":"2023-01-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}